Positron emission tomographic study in Parkinson’s disease—rigid vs tremor type

Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Using 15O (O2, CO2) and 18F-fluoro-deoxyglucose, a positron emission tomographic study was carried out to elucidate ongoing changes in a whole brain in cases with rigid- and tremor-type Parkinson’s disease (PA), respectively. For comparison, cases with essential tremor and normal control were also examined. MRI and XCT images and depth recording from basal ganglia during the course of stereotactic thalamotomy were considered together.

In rigid-type PA, cortical rCBF, rCMRO2 and rCMRGl were significantly reduced. However, 18FDG in basal ganglia (especially in the region of putamen and pallidum) was maintained in the normal or even in higher level. Microrecording also revealed reduced electrical activity in caudate nucleus, in contrast with higher activity in pallidum.

In tremor-type PA, the reduction of cortical metabolic rate was moderate, and activity in the caudate was maintained.

Metabolic rate in essential tremor and normal case seemed to be similar: it was high in cortical level and basasl ganglia (Cd was more active than putamen-pallidum).

Different metabolic features between rigid- and tremor- type PA were emphasized.


Positron Emission Tomography Essential Tremor Positron Emission Tomography Study Cerebral Metabolic Rate Depth Recording 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brooks DJ, Frackowiak RSJ (1989) PET and movement disorders. J Neurol Neurosurg Psychiatry [Special Suppl]: 68–77Google Scholar
  2. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA (1990) The metabolic anatomy of Parkinson’s disease: complementary [18F] fluorodeoxyglucose and [18F] fluoro-dopa positron emission tomographic studies. Movement Disorders 5: 203–213PubMedCrossRefGoogle Scholar
  3. Hirato M, Kawashima Y, Shibazaki T, Shibasaki T, Ohye C (1989) Pathophysiology of parkinsonian rigidity (japanese). Functional Neurosurg 28: 1–9Google Scholar
  4. Kuhl DE, Metter EJ, Reige WH (1984) Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F]Fluorodeoxyglucose method. Ann Neurol 15: 419–424PubMedCrossRefGoogle Scholar
  5. Leenders KL, Wolfson L, Gibbs JM, Wise RJS, Causon R, Jones T, Legg, NJ (1985) The effects of L-dopa on regional cerbral blood flow and oxygen metabolism in patients with parkinson’s disease. Brain 108: 171–191PubMedCrossRefGoogle Scholar
  6. Martin WR (1985) Positron emission tomography in movement disorders. Can J Neurol Sci 12: 6–10PubMedGoogle Scholar
  7. Ohye C (1985) Studies on the functional disorders of the brain by PET scan (japanese). Proc 17th Japan Conference on Radiation and Radioisotopes, pp 127–132Google Scholar
  8. Ohye C (1988) Selective thalamotomy for movement disorders: microrecording stimulation, techniques and results. In: Lunsford LD (ed) Modern stereotactic surgery. Martius Nijhoff, Boston, pp 315–331Google Scholar
  9. Ohye C (1989) A new aspect of parkinsonian tremor and rigidity (japanese). Internal Med 63: 831–836Google Scholar
  10. Ohye C (1990) Regional cerebral metabolism in movement disorders (japanese). In: Nagatsu T, et al (eds) Receptors of the brain and movement. Heibonsha, Tokyo, pp 135–145Google Scholar
  11. Ohye C, Shibazaki T, Hirato M, Kawashima Y, Matsumura M, Shibasaki T (1990) Neural activity of the basal ganglia in Parkinson’s disease studied by depth recording and PET scan. In: Bernardi (ed) Basal Ganglia III. Plenum, New York London, pp 637 – 644Google Scholar
  12. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kühl DE (1979) Topographic measurement of local cerebral glucose metabolic rate in humans with [F-18]2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6: 371–388PubMedCrossRefGoogle Scholar
  13. Phelps ME, Maziotta JC (1985) Positron emission tomography: human brain function and biochemistry. Science 228: 799–809PubMedCrossRefGoogle Scholar
  14. Raichle ME, Perlmutter JS, Fox PT (1984) Parkinson’s disease: metabolic and pharmacological approaches with positron emission tomography. Ann Neurol [Suppl 15]:S131 — 132PubMedCrossRefGoogle Scholar
  15. Rougemeont D, Baron JC, Collard P, Bustany P, Comar D, Agid Y (1984) Local cerebral glucose utilisation in treated and untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 47:824–830CrossRefGoogle Scholar
  16. Shibasaki T (1984) Analysis of human cerebral functions using positron emission tomography (PET) — A review (japanese). Progr Neurosci 28:211 — 228Google Scholar
  17. Shibasaki T (1989) Cerebral functions evaluated by blood flow studies in normal andpathological states (japanese). Neurosci Rev 3:150–178Google Scholar
  18. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M, (1977) the [14C]desoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897–916.PubMedCrossRefGoogle Scholar
  19. Wagner HN (1986) Images of the brain: past and prologue. J Nucl Med 27:1929–1937PubMedGoogle Scholar
  20. Wolfson LI, Leenders KL, Brown LL, Jones T (1985) Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson’s disease. Neurology 35:1399—1405PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • C. Ohye
    • 1
  1. 1.Department of NeurosurgeryGunma University School of MedicineMaebashi, GunmaJapan

Personalised recommendations